Phase 2Recruiting
Prevent Cardiac Surgery Associated AKI Trial
Efficacy of Mitochondrial Directed Therapy in Prevention of Cardiac Surgery Associated AKI Prevent Cardiac Surgery Associated AKI Trial (Prevent CSA-AKI Trial)
- Sponsor
- George Washington University (Academic or other)
- Enrolment
- 242 planned
- Conditions
- Renal Failure; Coronary Artery Disease; Surgery; Surgery-Complications
- Interventions
- CoQ10 1200 mg orally with Glutathione 1000 mg orally; Group B: Placebo CoQ10 orally and Placebo Glutathione orally
- Ages
- adults, older adults
- Registry
- NCT06620523
Full record on ClinicalTrials.gov
From the registry
Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.
Primary outcomes
- AKI incidence reduction
History
Study completion expected
Primary completion expected
Last registry update
Registered
Started